newsfilter
← Latest News
ACCESS Newswire·

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA ,